The WHO global influenza surveillance and response system (GISRS)—A future perspective

Influenza and other Respiratory Viruses

Volumn 12, Issue 5, 2018, Pages 551-557

  Hay, Alan J ^a   McCauley, John W ^a  

^a THE FRANCIS CRICK INSTITUTE   (United Kingdom)

Author keywords

GISRS, global influenza surveillance and response system; influenza; surveillance, WHO

Indexed keywords

AMANTADINE; INFLUENZA VACCINE;

ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; AVIAN INFLUENZA (H5N1); DISEASE CLASSIFICATION; DISEASE SURVEILLANCE; HUMAN; INFECTION CONTROL; INFLUENZA; INFLUENZA A; NEXT GENERATION SEQUENCING; NONHUMAN; NOTE; PANDEMIC INFLUENZA; PRIORITY JOURNAL; PUBLIC HEALTH; SEASONAL INFLUENZA; VIRUS CHARACTERIZATION; VIRUS MORPHOLOGY; WORLD HEALTH ORGANIZATION; ZOONOSIS; CLASSIFICATION; COMMUNICABLE DISEASE CONTROL; EPIDEMIC; EPIDEMIOLOGICAL MONITORING; GLOBAL HEALTH; INTERNATIONAL COOPERATION; ISOLATION AND PURIFICATION; ORGANIZATION AND MANAGEMENT; ORTHOMYXOVIRIDAE; VIROLOGY;

COMMUNICABLE DISEASE CONTROL; EPIDEMICS; EPIDEMIOLOGICAL MONITORING; GLOBAL HEALTH; HUMANS; INFLUENZA, HUMAN; INTERNATIONAL COOPERATION; ORTHOMYXOVIRIDAE; WORLD HEALTH ORGANIZATION;

EID: 85051288090     PISSN: 17502640     EISSN: 17502659     Source Type: Journal    
DOI: 10.1111/irv.12565     Document Type: Note

References (67)

1. G20. Germany 2017, Berlin Declaration of the G20 Health Ministers. Together Today for a Healthy Tomorrow. 2017 https://www.bundesgesundheitsministerium.de/fileadmin/Dateien/3_Downloads/G/G20-Gesundheitsministertreffen/G20_Health_Ministers_Declaration_engl.pdf. Accessed May 14, 2018
2. Ziegler T, Mamahit A, Cox NJ. 65 years of influenza surveillance by a WHO-coordinated global network - this issue. Influenza Other Respir Viruses. 2018; https://doi.org/10.1111/irv.12570
3. Iuliano AD, Roguski KM, Chang HH, et al. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. Lancet. 2018;391:1285-1300. https://doi.org/10.1016/S0140-6736(17)33293-2
4. Skehel JJ, Schild GC. The polypeptide composition of influenza A viruses. Virology. 1971;44:396-408
5. Skehel JJ, Hay AJ. Nucleotide sequences at the 5′ termini of influenza virus RNAs and their transcripts. Nucleic Acids Res. 1978;5:1207-1219
6. Pereira HG, Tumova B, Webster RG. Antigenic relationship between influenza A viruses of human and avian origins. Nature. 1967;215:982-983
7. Tumova B, Schild GC. Antigenic relationships between type a influenza viruses of human, porcine, equine, and avian origin. Bull World Health Organ. 1972;47:453-460
8. Kaplan M, Beveridge WI. WHO coordinated research on the role of animals in influenza epidemiology: introduction. Bull World Health Organ. 1972;47:439-448
9. Wiley DC, Wilson IA, Skehel JJ. Structural identification of the antibody-binding sites of Hong Kong influenza haemagglutinin and their involvement in antigenic variation. Nature. 1981;289:373-378
10. Xiong X, McCauley JW, Steinhauer DA. Receptor binding properties of the influenza virus hemagglutinin as a determinant of host range. Curr Top Microbiol Immunol. 2014;385:63-91
11. Skehel JJ, Wiley DC. Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu Rev Biochem. 2000;69:531-569
12. Isaacs A, Lindenmann J. Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci. 1957;147:258-267
13. Townsend AR, Rothbard J, Gotch FM, Bahadur G, Wraith D, McMichael AJ. The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides. Cell. 1986;44:959-968
14. Gubareva LV, Besselaar TG, Daniels RS, et al. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2015-2016. Antiviral Res. 2017;146:12-20
15. Hay AJ, Wolstenholme AJ, Skehel JJ, Smith MH. The molecular basis of the specific anti-influenza action of amantadine. EMBO J. 1985;4:3021-3024
16. Chizhmakov IV, Geraghty FM, Ogden DC, Hayhurst A, Antoniou M, Hay AJ. Selective proton permeability and pH regulation of the influenza virus M2 channel expressed in mouse erythroleukaemia cells. J Physiol. 1996;494(Pt 2):329-336
17. Deyde VM, Xu X, Bright RA, et al. Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide. J Infect Dis. 2007;196:249-257
18. Lackenby A, Hungnes O, Dudman SG, et al. Emergence of resistance to oseltamivir among influenza A(H1N1) viruses in Europe. Euro Surveill 2008;13:pii=8026
19. Hampson A, Barr I, Cox N, et al. Improving the selection and development of influenza vaccine viruses - Report of a WHO informal consultation on improving influenza vaccine virus selection, Hong Kong SAR, China, 18-20 November 2015. Vaccine. 2017;35:1104-1109
20. Peiris JS, Yu WC, Leung CW, et al. Re-emergence of fatal human influenza A subtype H5N1 disease. Lancet. 2004;363:617-619
21. World Health Organization. Pandemic Influenza Preparedness (PIP) Framework. 2011. http://www.who.int/influenza/pip/en/. Accessed May 14, 2018
22. World Health Organisation. Review of the Pandemic Influenza Preparedness Framework. 2016. http://apps.who.int/gb/ebwha/pdf_files/EB140/B140_16-en.pdf?ua=1. Accessed May 14, 2018
23. Convention on Biological Diversity, The Nagoya Protocol on Access and Benefit-sharing. https://www.cbd.int/abs/. Accessed May 14, 2018
24. Ksiazek TG, Erdman D, Goldsmith CS, et al. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med. 2003;348:1953-1966
25. Drosten C, Gunther S, Preiser W, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med. 2003;348:1967-1976
26. Bermingham A, Chand MA, Brown CS, et al. Severe respiratory illness caused by a novel coronavirus, in a patient transferred to the United Kingdom from the Middle East, September 2012. Euro Surveill. 2012;17:20290
27. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med. 2012;367:1814-1820
28. World Health Organisation. WHO Global Respiratory Syncytial Virus Surveillance. www.who.int/influenza/rsv/en/. Accessed May 14, 2018
29. Hirve S, Lambach P, Paget J, Vandemaele K, Fitzner J, Zhang W. Seasonal influenza vaccine policy, use and effectiveness in the tropics and subtropics - a systematic literature review. Influenza Other Respir Viruses. 2016;10:254-267
30. Hirve S, Newman LP, Paget J, et al. Influenza seasonality in the tropics and subtropics - when to vaccinate? PLoS One. 2016;11:e0153003
31. World Health Organisation, Implementation of the International Health Regulations (2005): Report of the Review Committee on the Functioning of the International Health Regulations (2005) in relation to Pandemic (H1N1) 2009. 2011. http://apps.who.int/gb/ebwha/pdf_files/WHA64/A64_10-en.pdf?ua=1. Accessed May 14, 2018
32. Zhang W, Hirve S, Kieny MP. Seasonal vaccines - Critical path to pandemic influenza response. Vaccine. 2017;35:851-852
33. Poon LL, Song T, Rosenfeld R, et al. Quantifying influenza virus diversity and transmission in humans. Nat Genet. 2016;48:195-200
34. World Health Organisation. Influenza: Laboratory methodologies for testing the antiviral susceptibility of influenza viruses. http://www.who.int/influenza/gisrs_laboratory/antiviral_susceptibility/en/. Accessed May 14, 2018
35. GISAID. The Global Initiative on Sharing All Influenza Data. https://www.gisaid.org/. Accessed May 14, 2018
36. Elbe S, Buckland-Merrett G. Data, disease and diplomacy: GISAID's innovative contribution to global health. Global Challenges. 2017;1:33-46
37. World Health Organisation. Expert Committee on Influenza - First Report, 1953. http://apps.who.int/iris/bitstream/10665/40208/1/WHO_TRS_64.pdf. Accessed May 14, 2018
38. Dormitzer PR, Suphaphiphat P, Gibson DG, et al. Synthetic generation of influenza vaccine viruses for rapid response to pandemics. Sci Transl Med 2013;5:185ra68. https://doi.org/10.1126/scitranslmed.3006368
39. Barr IG, Russell C, Besselaar TG, et al. WHO recommendations for the viruses used in the 2013-2014 Northern Hemisphere influenza vaccine: epidemiology, antigenic and genetic characteristics of influenza A(H1N1)pdm09, A(H3N2) and B influenza viruses collected from October 2012 to January 2013. Vaccine. 2014;32:4713-4725. https://doi.org/10.1016/j.vaccine.2014.02.014
40. GLoPID-R. Global Research Collaboration for Infectious Disease Preparedness. https://www.glopid-r.org/. Accessed May 14, 2018
41. McCauley JW. Viruses: model to accelerate epidemic responses. Nature. 2017;542:414
42. Flannery B, Zimmerman RK, Gubareva LV, et al. Enhanced Genetic Characterization of Influenza A(H3N2) Viruses and Vaccine Effectiveness by Genetic Group, 2014-2015. J Infect Dis. 2016;214:1010-1019
43. Pebody R, Warburton F, Andrews N, et al. Effectiveness of seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2014/15 end of season results. Euro Surveill 2015;20. https://doi.org/10.2807/1560-7917.ES.2015.20.36.30013
44. Harvey WT, Benton DJ, Gregory V, et al. Identification of low- and high-impact hemagglutinin amino acid substitutions that drive antigenic drift of influenza A(H1N1) viruses. PLoS Pathog. 2016;12:e1005526
45. Morris DH, Gostic KM, Pompei S, et al. Predictive modeling of influenza shows the promise of applied evolutionary biology. Trends Microbiol. 2018;26:102-118. https://doi.org/10.1016/j.tim.2017.09.004
46. Li C, Hatta M, Burke DF, et al. Selection of antigenically advanced variants of seasonal influenza viruses. Nat Microbiol. 2016;1:16058
47. Lin YP, Xiong X, Wharton SA, et al. Evolution of the receptor binding properties of the influenza A(H3N2) hemagglutinin. Proc Natl Acad Sci U S A. 2012;109:21474-21479
48. Neher RA, Bedford T. nextflu: real-time tracking of seasonal influenza virus evolution in humans. Bioinformatics. 2015;31:3546-3548
49. FluSurver. Influenza Surveillance - prepared for the next wave. http://flusurver.bii.a-star.edu.sg/. Accessed May 14, 2018
50. Xiong X, Coombs PJ, Martin SR, et al. Receptor binding by a ferret-transmissible H5 avian influenza virus. Nature. 2013;497:392-396
51. Xiong X, Martin SR, Haire LF, et al. Receptor binding by an H7N9 influenza virus from humans. Nature. 2013;499:496-499
52. Imai M, Watanabe T, Hatta M, et al. Experimental adaptation of an influenza H5 HA confers respiratory droplet transmission to a reassortant H5 HA/H1N1 virus in ferrets. Nature. 2012;486:420-428
53. Herfst S, Schrauwen EJ, Linster M, et al. Airborne transmission of influenza A/H5N1 virus between ferrets. Science. 2012;336:1534-1541
54. Cox NJ, Trock SC, Burke SA. Pandemic preparedness and the Influenza Risk Assessment Tool (IRAT). Curr Top Microbiol Immunol. 2014;385:119-136
55. Zhang Q, Shi J, Deng G, et al. H7N9 influenza viruses are transmissible in ferrets by respiratory droplet. Science. 2013;341:410-414
56. Su S, Gu M, Liu D, et al. Epidemiology, evolution, and pathogenesis of H7N9 influenza viruses in five epidemic waves since 2013 in China. Trends Microbiol. 2017;25:713-728
57. Garten RJ, Davis CT, Russell CA, et al. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science. 2009;325:197-201
58. Infection CfDCa Reported Infections with Variant Influenza Viruses in the United States since 2005, 2016
59. Dowdle WR. Influenza pandemic periodicity, virus recycling, and the art of risk assessment. Emerg Infect Dis. 2006;12:34-39
60. World Health Organisation, WHO Public Health Research Agenda for Influenza - 2017 update http://www.who.int/influenza/resources/research/publication_research_agenda_2017/en/. Accessed May 14, 2018
61. Schotsaert M, De Filette M, Fiers W, Saelens X. Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments. Expert Rev Vaccines. 2009;8:499-508
62. Krammer F, Palese P, Steel J. Advances in universal influenza virus vaccine design and antibody mediated therapies based on conserved regions of the hemagglutinin. Curr Top Microbiol Immunol. 2015;386:301-321
63. Marcelin G, DuBois R, Rubrum A, Russell CJ, McElhaney JE, Webby RJ. A contributing role for anti-neuraminidase antibodies on immunity to pandemic H1N1 2009 influenza A virus. PLoS One. 2011;6:e26335
64. Altenburg AF, Rimmelzwaan GF, de Vries RD. Virus-specific T cells as correlate of (cross-) protective immunity against influenza. Vaccine. 2015;33:500-506
65. Kreijtz JH, Goeijenbier M, Moesker FM, et al. Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1/2a clinical trial. Lancet Infect Dis. 2014;14:1196-1207
66. Koszalka P, Tilmanis D, Hurt AC. Influenza antivirals currently in late-phase clinical trial. Influenza Other Respir Viruses. 2017;11:240-246
67. McKimm-Breschkin JL, Jiang S, Hui DS, Beigel JH, Govorkova EA, Lee N. Prevention and treatment of respiratory viral infections: presentations on antivirals, traditional therapies and host-directed interventions at the 5th ISIRV Antiviral Group conference. Antiviral Res. 2017;149:118-142